期刊文献+

辛伐他汀对大鼠吸烟所致肺动脉高压的影响

下载PDF
导出
摘要 目的通过使用辛伐他汀对吸烟所致肺动脉高压大鼠模型的治疗,探讨辛伐他汀对大鼠吸烟所致肺动脉高压的影响及其机制。方法将36只雄性SD大鼠随机分为正常组,12只;模型组,12只;辛伐他汀干预组,12只。观测指标:采用导管法和多导生理仪测定平均肺动脉压(mPAP);免疫组化法测定高敏感C反应蛋白(hs-CRP)含量。结果模型组大鼠及干预组大鼠血清中的hs-CRP含量比正常组数值明显增高(P<0.01);模型组及干预组mPAP值明显高于同期正常组数值(P<0.01),干预组hs-CRP明显低于模型组(P<0.05),干预组mPAP明显低于模型组(P<0.05)。结论辛伐他汀干预后可使大鼠动脉压升高较模型组数值低,炎症标记物hs-CRP升高较模型组低。辛伐他汀对mPAP升高的抑制可能与抑制炎症反应,减少炎症因子产生有关。
作者 陈波 王雪梅
出处 《中外医疗》 2008年第13期76-77,共2页 China & Foreign Medical Treatment
  • 相关文献

参考文献10

  • 1[1]谢敏强,方理本.药理学前沿,(哮喘和COPD的新概念及新药)[M].北京:科学出版社,2003:8.
  • 2[2]Sin DD,Man SF.Is systemic inflammation responsible for pulmonary hypertension in COPD[J].Chest,2006,130(2):310-312.
  • 3侯翠红,李亚辉,王文,程显声.自发性高血压大鼠右心室压、肺动脉压变化的观察[J].中国分子心脏病学杂志,2007,7(1):37-38. 被引量:3
  • 4张珍祥.肺动脉高压诊断和治疗进展[J].实用医院临床杂志,2007,4(1):5-7. 被引量:17
  • 5[5]Rubin LJ.Therapy of pulmonary hypertension:the evolution from vasodilators to antiproliferative agents[J].Am J Respir Crit Care Med,2002,166(10):1308-1309.
  • 6荆志成,主译.肺动脉高压康复指南.北京:人民军医出版社,2006:36.
  • 7[7]Joppa P,Petrasova D,Stancak B,Tkacova R.Systemic inflammation in patients with OPD and pulmonary hrpertension[J].Chest,2006,130(2):326-33.
  • 8夏秀琼,程德云,苏巧俐,陈小菊,杨莉.辛伐他汀对大鼠低氧性肺动脉高压的作用[J].中华结核和呼吸杂志,2007,30(5):386-388. 被引量:10
  • 9[10]Lee JH,Lee DS,Kim EK,et al.Simvastatin inhibits cigarette smoking-induced emphysema and pulmonary hypertension in rat lungs[J].Am J Respir Crit Care Med,2005,172(8):987~993.
  • 10[11]Wright JL,Levy RD,Churg A.Pulmonary hypertension in chronic obstructive pulmonary d.isease:current theories of pathogenesis and their implications for treatment[J].Thorax,2005,60(7):605~609.

二级参考文献23

  • 1[1]Burrows B,Kettel LJ,Niden AH,et al.Patterns of cardiovascular dysfunction in chronic obstructive lung disease[J].N EngI J Med,1972,286(17):912-918.
  • 2[2]Weitzenblum E,Loiseau A,Hirth C,et al.Course of pulmonary hemodynamics in patients with chronic obstructive pulmonary disease[J].Chest,1979,75(6):656-662.
  • 3[3]Chetty KG,Brown SE,Light RW.Identification of pulmonary hypertension in chronic obstructive pulmonary disease from routine chest radiographs[J].Am Rev Respir Dis,1982,126(2):338-341.
  • 4[4]Malik AS,Warshafsky S,Lehrman S.Meta-analysis of the long-term effect of nifedipine for pulmonary hypertension[J].Arch Intern Med,1997,157(6):621-625.
  • 5[5]Van Mieghem W,Van den Brande P,De Waele R,et al.Evaluation of the safety and efficacy of amrinone in chronic obstructive lung disease with cor pulmonale[J].Acta Cardiol,1990,45(1):57-64.
  • 6[6]Jones K,Higenbottam T,Wallwork J.Pulmonary vasodilation with prostacyclin in primary and secondary pulmonary hypertension[J].Chest,1989,96(4):784-789.
  • 7[7]Yap LB,Mukerjee D,Timms PM,et al.Natriuretic peptides,respiratory disease,and the right heart[J].Chest,2004,126(4):1330-1336.
  • 8[8]Zhao YD,Courtman DW,Ng DS,et al.Microvascular Regeneration in Established Pulmonary Hypertension by Angiogenic Gene Transfer[J].Am J Respir Cell Mol Biol,2006,35(2):182-189.
  • 9[1]Unger F,Ganten D,Lang RE.Effect of converting enzyme inhibitors on tissue converting enzyme and angiotensin Ⅱ:therapeatic implication.Am J cardiol,1987,24:59 (10):18D-22D.
  • 10[2]Chatziantoniou C,Pauti MD,et al.Regulation of rein realse is impaired after nitric oxide inhibition.Kidney Int,1996,49:626-633.

共引文献28

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部